About Ducentis BioTheapeutics
Ducentis BioTheapeutics is a company based in Witney (United Kingdom) founded in 2015 was acquired by Arcutis in September 2022.. Ducentis BioTheapeutics has raised $2.29 million across 5 funding rounds from investors including Arcutis, Oxford Technology and LifeArc. The company has 6 employees as of October 31, 2021. Ducentis BioTheapeutics operates in a competitive market with competitors including BeiGene, Biogen, Moderna, UCB and Incyte, among others.
- Headquarter Witney, United Kingdom
- Employees 6 as on 31 Oct, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Ducentis Biotherapeutics Ltd.
- Date of Incorporation 12 Nov, 2014
- Jurisdiction 10 TEMPLE BACK, BRISTOL, UNITED KINGDOM
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ducentis BioTheapeutics
Ducentis BioTheapeutics has successfully raised a total of $2.29M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $1.9 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Seed — $1.9M
-
First Round
First Round
(13 Jul 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Seed - Ducentis BioTheapeutics | Valuation | LifeArc | |
| Mar, 2018 | Amount | Seed - Ducentis BioTheapeutics | Valuation |
investors |
|
| Mar, 2017 | Amount | Seed - Ducentis BioTheapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ducentis BioTheapeutics
Ducentis BioTheapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Arcutis, Oxford Technology and LifeArc. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage micro-VC investments are focused on UK companies.
|
Founded Year | Domain | Location | |
|
Medical research and treatments are supported by the community foundation.
|
Founded Year | Domain | Location | |
|
Immunotherapeutic solutions for dermatological conditions are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ducentis BioTheapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ducentis BioTheapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ducentis Biotheapeutics Comparisons
Competitors of Ducentis BioTheapeutics
Ducentis BioTheapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biogen, Moderna, UCB and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ducentis Biotheapeutics
Frequently Asked Questions about Ducentis BioTheapeutics
When was Ducentis BioTheapeutics founded?
Ducentis BioTheapeutics was founded in 2015.
Where is Ducentis BioTheapeutics located?
Ducentis BioTheapeutics is headquartered in Witney, United Kingdom. It is registered at Witney, Oxfordshire, United Kingdom.
Is Ducentis BioTheapeutics a funded company?
Ducentis BioTheapeutics is a funded company, having raised a total of $2.29M across 5 funding rounds to date. The company's 1st funding round was a Seed of $199.11K, raised on Jul 13, 2015.
How many employees does Ducentis BioTheapeutics have?
As of Oct 31, 2021, the latest employee count at Ducentis BioTheapeutics is 6.
What does Ducentis BioTheapeutics do?
Founded in 2015, Ducentis BioTheapeutics operates as a UK-based preclinical biotech firm in Witney, focusing on therapeutics for inflammatory and auto-immune conditions. An existing protein is modified to enhance its immunoregulatory role, targeting the CD200CD200R pathway to suppress immune responses. A portfolio of CD200 molecules is advanced through collaborations with Prosarix, Syngene, GVK Bio, and KWS BioTest, supported by seed funding from Oxford Technology.
Who are the top competitors of Ducentis BioTheapeutics?
Ducentis BioTheapeutics's top competitors include Moderna, BeiGene and Serum Institute of India.
Who are Ducentis BioTheapeutics's investors?
Ducentis BioTheapeutics has 3 investors. Key investors include Arcutis, Oxford Technology, and LifeArc.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.